Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Markers and diagnostic reagents for the diagnosis or prognosis of lung cancer

A technology for diagnostic reagents and prognosis, applied in the field of diagnostic markers, can solve the problems of time-consuming LCM, complex sample preparation steps, and a large number of sample materials.

Pending Publication Date: 2019-01-25
CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI +1
View PDF5 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, LCM is time-consuming and requires specialized equipment
De Petris et al. developed a new sample preparation method to remove blood contaminants from lung tissue for proteomic analysis, but this method required complex sample preparation steps and a large amount of sample material

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Markers and diagnostic reagents for the diagnosis or prognosis of lung cancer
  • Markers and diagnostic reagents for the diagnosis or prognosis of lung cancer
  • Markers and diagnostic reagents for the diagnosis or prognosis of lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0088] Example 1. Identification of differentially expressed proteins associated with early recurrence of SCC using iTRAQ-based 2D LC-MS / MS

[0089] In order to identify proteins associated with the prognosis of SCC patients, the inventors compared the expression of proteins in primary SCC tumor tissues from patients with early recurrence (ER, within 10 months) and patients with late recurrence (LR, >30 months) after surgery. differential expression. Twenty paired (according to patients' similar clinicopathological characteristics, including sex, smoking history, age, and TNM status) SCC tumor samples were subjected to iTRAQ marker quantitative proteomic analysis. The inventors identified a total of 4194 proteins (FDR Figure 7 . 136 proteins (72 up-regulated and 64 down-regulated proteins) showed significant differential expression between ER and LR (>1.5-fold difference in expression level in at least 4 paired samples, p-value figure 1 shown.

Embodiment 2

[0090] Example 2, Bioinformatics Analysis and Comprehensive Literature Survey of Differentially Expressed Proteins

[0091] In order to study the biological functions of the identified differentially expressed proteins, the inventors performed protein network analysis and Gene Ontology (GO) analysis. Network analysis of 136 significantly altered proteins was performed using IPA software. Such as figure 2 (A-B), The top 2 disease and functional networks identified by IPA analysis are "Cell Motility, Inflammatory Response, Hair and Skin Development and Function" (Score = 43) and "Cancer, Blood Disease, Cell Development" (Score = 26) . The results showed that the significantly altered proteins in ER and LR patients were closely related to cell motility and cancer network. GO analysis was performed on up-regulated and down-regulated proteins, respectively, using DAVIDBioinformatics resource 6.7. The top five GO terms identified in GO as image 3 shown. GO analysis revealed ...

Embodiment 3

[0096] Example 3, the correlation between the expression of DDX56 and the survival period of lung cancer patients

[0097] To further evaluate the correlation between DDX56 and the upregulated proteins in the top 10 ER groups and the overall survival rate of cancer patients, the inventors used two online survival analysis software: SurvExpress and KMplot.

[0098] SurvExpress survival analysis is based on a microarray data set of 130 SCC patients that has been published. The inventors analyzed DDX56 alone and also showed that the high gene expression level of DDX56 was significantly related to the poor prognosis of SCC patients (hazard ratio=1.74, logrank P value=0.0261 ; Figure 4 , A).

[0099] Next, the present inventors used KMplot to further investigate the correlation between DDX56 and cancer prognosis in various cancer types. The KMplot background database included 2,437 lung adenocarcinoma patients with mean follow-ups of 69, 40, 49, and 33 months. The results showe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to markers and diagnostic reagents for the diagnosis or prognosis of lung cancer. The present invention discloses for the first time that DDX56 is significantly increasedin patients with early disease progression (= 12 months) after treatment of two major subtypes of small cell lung cancer (lung squamous cell carcinoma, lung adenocarcinoma), and that the increased expression of DDX56 significantly affects the overall survival of the patients. Therefore, DDX56 can be used as a diagnostic marker for early recurrence of lung squamous cell carcinoma or lung adenocarcinoma.

Description

technical field [0001] The invention belongs to the field of diagnostic markers, and more specifically, the invention relates to markers and diagnostic reagents for lung cancer diagnosis or prognosis. Background technique [0002] Lung cancer is the leading cause of cancer-related death worldwide, killing nearly 1.4 million people each year. Despite improvements in the diagnosis and treatment of lung cancer over the past decade, the overall 5-year patient survival rate remains below 16%. Nearly 85% of lung cancer cases are non-small cell lung cancer (NSCLC). Lung squamous cell carcinoma (Squamous Cell Carcinoma, SCC) is the second most common type of NSCLC, accounting for about 30% of all cases. Early treatment of NSCLC is mainly through surgical resection. However, among resected patients, prognosis varies widely. Even with successful resection, the 5-year survival rate of patients with squamous cell carcinoma of the lung is significantly lower than that of adenocarcino...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/574
CPCC12Q1/6886C12Q2600/118C12Q2600/158G01N33/57423G01N33/57484G01N2800/52
Inventor 曾嵘陈海泉吴庆庆罗晓阳李辰
Owner CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com